- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
EXEL Market Currents
more »
-
May 3 Exelixis (EXEL): Q1 EPS of -$0.18 beats by $0.01. Revenue of $18.5M (-48.4% Y/Y) misses by $7M. (PR)
Comment![Earnings, Healthcare]
EXEL in Focus
more »
EXEL Related Articles
more »
EXEL News
more »
-
at CNBC.com (Mar 27, 2012)
-
at MarketWatch.com (Feb 16, 2012)
-
at MarketWatch.com (Nov 1, 2011)
-
at MarketWatch.com (Oct 31, 2011)
-
at CNBC.com (Jul 29, 2011)
EXEL Press Releases and Filings
more »
-
Business Wire (May 16, 2012)
-
Business Wire (May 10, 2012)
-
Business Wire (May 3, 2012)
-
Business Wire (May 3, 2012)
-
Business Wire (May 2, 2012)
EXEL Latest Transcript
more »
EXEL Cramer
more »
-
Wed, Mar 28
-
Tue, Aug 23, 2011
-
Wed, Apr 27, 2011
EXEL Instablog posts
more »
EXEL vs. ETF Alternatives
Company Description
BUSINESS
Overview
We are committed to discovering, developing and commercializing innovative therapies for the treatment of cancer and other serious diseases. Through our integrated drug discovery and development activities, we are building a portfolio of novel compounds that we believe... More
